GlassScriptPhysician profile
Ronald J Russ
NPI 1467412460
$4,010.05
in general payments reported to CMS, 2019-2025
52 companies · $513 in 2025
The $513 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $231 · 2021: $748 · 2022: $821 · 2023: $851 · 2024: $560 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,923.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $917.01 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $324.80 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $246.36 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $232.86 | 2020-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.02 | 2019-2024 | Jardiance, Ofev |
| Pfizer INC. | $167.79 | 2019-2025 | |
| Abbott Laboratories | $153.09 | 2022-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $139.92 | 2021-2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $134.20 | 2019-2021 | |
| Amarin Pharma, INC. | $110.37 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $105.32 | 2020-2022 | |
| Novo Nordisk INC | $98.73 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $92.46 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $80.55 | 2023-2025 | Rexulti |
| Eisai INC. | $78.29 | 2021-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Russ listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.